HitGen Inc
SSE:688222

Watchlist Manager
HitGen Inc Logo
HitGen Inc
SSE:688222
Watchlist
Price: 12.33 CNY -0.48% Market Closed
Market Cap: 4.9B CNY
Have any thoughts about
HitGen Inc?
Write Note

HitGen Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HitGen Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
HitGen Inc
SSE:688222
Research & Development
-ÂĄ70.5m
CAGR 3-Years
9%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Research & Development
-ÂĄ1.4B
CAGR 3-Years
-23%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Research & Development
-ÂĄ483.8m
CAGR 3-Years
-49%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Research & Development
-ÂĄ788.4m
CAGR 3-Years
-39%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Research & Development
-ÂĄ238.3m
CAGR 3-Years
-6%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Research & Development
-ÂĄ76.9m
CAGR 3-Years
-166%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HitGen Inc
Glance View

Market Cap
4.9B CNY
Industry
Life Sciences Tools & Services

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.

Intrinsic Value
7.19 CNY
Overvaluation 42%
Intrinsic Value
Price

See Also

What is HitGen Inc's Research & Development?
Research & Development
-70.5m CNY

Based on the financial report for Dec 31, 2023, HitGen Inc's Research & Development amounts to -70.5m CNY.

What is HitGen Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-3%

Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for HitGen Inc have been 9% over the past three years , -3% over the past five years .

Back to Top